Skip Navigation LinksHome > May 4, 2001 - Volume 15 - Issue 7 > Primary genotypic resistance of HIV-1 to the fusion inhibito...
Research Letters

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients

Zöllner, Bernharda; Feucht, Heinz-Huberta; Schröter, Matthiasa; Schäfer, Petera; Plettenberg, Andreasb; Stoehr, Albrechtb; Laufs, Rainera

Free Access
Article Outline
Collapse Box

Author Information

aInstitut für Medizinische Mikrobiologie und Immunologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany; and bInstitut für Interdisziplinäre Infektiologie und Immunologie, Lohmühlenstrasse 5, D-20099 Hamburg, Germany.

Received: 12 September 2000; accepted: 30 January 2001.

The fusion inhibitor T-20 (DP178, pentafuside) represents a new substance class for the treatment of HIV infection. It is a short synthetic peptide corresponding to residues aa 127–162 within the transmembrane molecule gp41 of HIV-1 [1]. T-20 binds to the leucine zipper sequence (HR-1 domain) of gp41 and consequently inhibits transition to its fusion-active conformation [2], thereby blocking cell fusion and viral entry.

In our cohort, T-20 is of substantial interest for patients with failure of the currently available antiretroviral regimens. We have previously shown that only optimum treatment, including at least three sensitive drugs from at least two different substance classes, leads to the continuous suppression of the development of further resistance mutations [3]. As two resistance-associated mutations (G36S and V38M) against T-20 have already been described in vitro[4], it is important to know whether primary resistance to this drug can be detected in patients before the initiation of T-20 treatment. Therefore, we performed a cross-sectional analysis of the sequence variation in the N-terminus of the HR-1 domain, and determined the incidence of primary resistance to T-20 in long-term infected, heavily pretreated patients.

Thirty-nine caucasian patients were investigated. The duration of HIV infection was at least 5 years. They had received antiretroviral therapy for a mean of 4.6 years (range 2–12 years). T-20 resistance was determined genotypically from proviral DNA derived from peripheral blood lymphocytes. Peripheral blood lymphocytes were extracted from 10 ml ethylene diamine tetraacetic acid blood as described previously [5]. A 147 base pair region was amplified spanning a region from codons 6 to 54 of the gp41 molecule. A nested polymerase chain reaction was employed with primer pairs 1s (5′–TGGAGGAGGAGATATGAGG–3′)/2as (5′–CTACCAAGCCTCCTACTATC–3′) as external and 5s (5′–GCTTTRTTCMTTGGGTTCTT–3′)/6as (5′–CAGATGYTGTTGMGCCTC–3′) as internal primers. The amplification products were sequenced using BigDye termination chemistry on an automated sequencer (AbiPrism) with primers 5s and 6as. Both strands were sequenced and compared with a subtype B consensus sequence derived from an alignment of B sequences maintained at the Los Alamos HIV Sequence Database (accession no. X01762). In particular, codons 36 and 38 of the gp41 molecule were analysed for amino acid exchanges.

Amplification products were successfully obtained from 33 patients (84.6%). All had received nucleoside reverse transcriptase inhibitors for at least 3 years, in combination with either non-nucleoside reverse transcriptase inhibitors (n = 1), protease inhibitors (n = 23) or both classes of these compounds (n = 9). Compared with the consensus sequence, the concordance of nucleotide and amino acid sequences was 98 and 93.1% in our patients, respectively. The median sequence variation among all patients was 2/100 nucleotides (range 0-7/100) and 2/30 amino acids (range 0–5/30) across the analysed region. Of the 33 patients, none had amino acid exchanges at residues 36 and 38. Only one patient had a silent mutation at codon 36 (GGT to GGC). Therefore, primary genotypic resistance to T-20 could not be detected in any patient.

The results of our study show that primary resistance to T-20 is a rare event. A selection of G36S/V38M variants could not be detected even in long-term infected and heavily pretreated patients. This indicates that these variants do not have an advantage in terms of an immune escape during the course of infection or during previous antiretroviral treatment with drugs targeting reverse transcriptase or protease.

This has great impact on the initiation of a salvage regimen with T-20 as a component. As a result of a phase I/IIb open-label trial [6], the authors suggested that T-20 may be particularly useful in salvage regimens for patients who had failure of a previous highly active antiretroviral therapy. Our results show that T-20 represents a good alternative as a drug within salvage regimens because resistant variants were not found in pretreated patients. However, the favourable situation of T-20 primary resistance may change when T-20 is widely used in clinical practice because the transmission of T-20 resistant variants may occur as already described for other antiretroviral drugs [7]. In this case, T-20 primary resistance may not only be detectable but may also be clinically relevant even in treatment-naive patients.

Bernhard Zöllnera

Heinz-Hubert Feuchta

Matthias Schrötera

Peter Schäfera

Andreas Plettenbergb

Albrecht Stoehrb

Rainer Laufsa

Back to Top | Article Outline


1. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994, 91: 9770 –9774.

2. Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000, 295: 163 –168.

3. Zöllner B, Feucht HH, Weitner L, Adam A, Laufs R. Drug-resistant genotyping in HIV-1 therapy [Letter]. Lancet 1999, 354: 1120 –1121.

4. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72: 986 –993.

5. Zöllner B, Feucht HH, Hamann A, Laufs R. Influence of exogenous interleukin-2 on isolation of human immunodeficiency virus. Microbiol Immunol 1995, 39: 117 –121.

6. Kilby JM, Hopkins S, Venetta TM. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4: 1302 –1307.

7. Yerly S, Kaiser L, Race E, Bru JP, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354: 729 –733.

Cited By:

This article has been cited 34 time(s).

Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors
De Feo, CJ; Weiss, CD
Viruses-Basel, 4(): 3859-3911.
Resistance mutation in HIV entry inhibitors
Hanna, SL; Yang, CF; Owen, SM; Lal, RB
AIDS, 16(): 1603-1608.

Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors
Chinnadurai, R; Munch, J; Kirchhoff, F
AIDS, 19(): 1401-1405.

Antimicrobial Agents and Chemotherapy
SC29EK, a Peptide Fusion Inhibitor with Enhanced alpha-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
Naito, T; Izumi, K; Kodama, E; Sakagami, Y; Kajiwara, K; Nishikawa, H; Watanabe, K; Sarafianos, SG; Oishi, S; Fujii, N; Matsuoka, M
Antimicrobial Agents and Chemotherapy, 53(3): 1013-1018.
Journal of Clinical Virology
Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance
Chong, HH; Xu, SH; Zhang, CT; Nie, JH; Wang, YC
Journal of Clinical Virology, 45(3): 255-258.
Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients
Xu, L; Hue, S; Taylor, S; Ratcliffe, D; Workman, JA; Jackson, S; Cane, PA; Pillay, D
AIDS, 16(): 1684-1686.

Journal of Virology
Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2 ' F-RNA aptamers
Khati, M; Schuman, M; Ibrahim, J; Sattentau, Q; Gordon, S; James, W
Journal of Virology, 77(): 12692-12698.
Journal of Virology
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Eggink, D; Baldwin, CE; Deng, YQ; Langedijk, JPM; Lu, M; Sanders, RW; Berkhout, B
Journal of Virology, 82(): 6678-6688.
Virus Genes
Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon (R)) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy
Morozov, VA; Morozov, AV; Schurmann, D; Jessen, H; Kuchere, C
Virus Genes, 35(2): 167-174.
Methods for optimizing antiviral combination therapies
Beerenwinkel, N; Lengauer, T; Daumer, M; Kaiser, R; Walter, H; Korn, K; Hoffmann, D; Selbig, J
Bioinformatics, 19(): I16-i25.
Lancet Infectious Diseases
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development
Cooper, DA; Lange, JMA
Lancet Infectious Diseases, 4(7): 426-436.

Journal of Antimicrobial Chemotherapy
Resistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg, ML; Cammack, N
Journal of Antimicrobial Chemotherapy, 54(2): 333-340.
Virus Genes
Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1
Borkow, G; Lara, HH; Ayash-Rashkovsky, M; Tavor, E; Lapidot, A; Bentwich, Z; Honigman, A
Virus Genes, 29(2): 257-265.

Cellular and Molecular Life Sciences
Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance
Yin, PD; Das, D; Mitsuya, H
Cellular and Molecular Life Sciences, 63(): 1706-1724.
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
Cabrera, C; Marfil, S; Garcia, E; Martinez-Picado, J; Bonjoch, A; Bofill, M; Moreno, S; Ribera, E; Domingo, P; Clotet, B; Ruiz, L
AIDS, 20(): 2075-2080.

Reviews in Medical Virology
HIV fusion inhibitors
Qadir, MI; Malik, SA
Reviews in Medical Virology, 20(1): 23-33.
Enfuvirtide - The first fusion inhibitor for the treatment of patients with HIV-1 infection
Coleman, CI; Musial, BL; Ross, J
Formulary, 38(4): 204-+.

The appealing story of HIV entry inhibitors - From discovery of biological mechanisms to drug development
Castagna, A; Biswas, P; Beretta, A; Lazzarin, A
Drugs, 65(7): 879-904.

Journal of Clinical Virology
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro
Su, C; Melby, T; DeMasi, R; Ravindran, P; Heilek-Snyder, G
Journal of Clinical Virology, 36(4): 249-257.
Journal of Antimicrobial Chemotherapy
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
Aquaro, S; D'Arrigo, R; Svicher, V; Di Perri, G; Caputo, SL; Visco-Comandini, U; Santoro, M; Bertoli, A; Mazzotta, F; Bonora, S; Tozzi, V; Bellagamba, R; Zaccarelli, M; Narciso, P; Antinori, A; Perno, CF
Journal of Antimicrobial Chemotherapy, 58(4): 714-722.
Dando, TM; Perry, CM
Drugs, 63(): 2755-2766.

HIV-1 drug-resistance and drug-dependence
Baldwin, C; Berkhout, B
Retrovirology, 4(): -.
HIV Clinical Trials
Enfuvirtide: Antiretroviral class 4, drug 1
Asboe, D
HIV Clinical Trials, 5(1): 1-6.

Journal of Virology
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
Baldwin, CE; Sanders, RW; Deng, YQ; Jurriaans, S; Lange, JM; Lu, M; Berkhout, B
Journal of Virology, 78(): 12428-12437.
Antimicrobial Agents and Chemotherapy
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
Xu, L; Pozniak, A; Wildfire, A; Stanfield-Oakley, SA; Mosier, SA; Ratcliffe, D; Workman, J; Joall, A; Myers, R; Smit, E; Cane, PA; Greenberg, AL; Pillay, D
Antimicrobial Agents and Chemotherapy, 49(3): 1113-1119.

Enfermedades Infecciosas Y Microbiologia Clinica
Spanish recommendations for proper use of enfuvirtide
Ribera, E; Moreno, S; Viciana, P; Echevarria, S; Flores, J; Frances, A; Gomez-Sirvent, JL; Gonzalez, J; Hernandez-Quero, J; Lozano, F; Mallolas, J; Munoz, A; Ocampo, A; Portillan, J; Pulido, F; Rivero, A; Santos, J; Soriano, V; Antela, A; Arazo, P; Arribas, JR; Cervantes, M; Domingo, P
Enfermedades Infecciosas Y Microbiologia Clinica, 25(2): 131-142.

Journal of Clinical Virology
Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients
Carmona, R; Perez-Alvarez, L; Munoz, M; Casado, G; Delgado, E; Sierra, M; Thomson, M; Vega, Y; de Parga, EV; Contreras, G; Medrano, L; Najera, R
Journal of Clinical Virology, 32(3): 248-253.
Journal of Virology
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
Labrosse, B; Labernardiere, JL; Dam, E; Trouplin, V; Skrabal, K; Clavel, F; Mammano, F
Journal of Virology, 77(2): 1610-1613.
American Journal of Health-System Pharmacy
Enfuvirtide: First fusion inhibitor for treatment of HIV infection
Jamjian, MC; McNicholl, IR
American Journal of Health-System Pharmacy, 61(): 1242-1247.

Expert Opinion on Pharmacotherapy
Enfuvirtide: the first HIV fusion inhibitor
Lazzarin, A
Expert Opinion on Pharmacotherapy, 6(3): 453-464.

Clinical Therapeutics
Enfuvirtide: A fusion inhibitor for the treatment of HIV infection
Fung, HB; Guo, Y
Clinical Therapeutics, 26(3): 352-378.

Current Medicinal Chemistry
Inhibiting HIV-1 entry with fusion inhibitors
Baldwin, CE; Sanders, RW; Berkhout, B
Current Medicinal Chemistry, 10(): 1633-1642.

Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants
Villahermosa, ML; Perez-Alvarez, L; Carmona, R; Cuevas, MT; Thomson, MM; Medrano, L; Parga, EV; Delgado, E; Pedreira, JD; Nájera, R
AIDS, 17(7): 1083-1086.

JAIDS Journal of Acquired Immune Deficiency Syndromes
Uncommon Mutations at Residue Positions Critical for Enfuvirtide (T-20) Resistance in Enfuvirtide-Naive Patients Infected With Subtype B and Non-B HIV-1 Strains
Roman, F; Gonzalez, D; Lambert, C; Deroo, S; Fischer, A; Baurith, T; Staub, T; Boulmé, R; Arendt, V; Schneider, F; Hemmer, R; Schmit, J
JAIDS Journal of Acquired Immune Deficiency Syndromes, 33(2): 134-139.

PDF (3813)
Back to Top | Article Outline

© 2001 Lippincott Williams & Wilkins, Inc.


Article Level Metrics